Equities Analysts Set Expectations for Innoviva Q2 Earnings

Innoviva, Inc. (NASDAQ:INVA) – Stock analysts at HC Wainwright cut their Q2 2027 earnings per share (EPS) estimates for shares of Innoviva in a research report issued to clients and investors on Monday, June 1st. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will post earnings of $0.63 per share for the quarter, down from their previous forecast of $0.65. HC Wainwright has a “Buy” rating and a $46.00 price target on the stock. The consensus estimate for Innoviva’s current full-year earnings is $1.96 per share. HC Wainwright also issued estimates for Innoviva’s Q3 2027 earnings at $0.61 EPS, Q4 2027 earnings at $0.67 EPS and FY2027 earnings at $2.43 EPS.

INVA has been the subject of several other reports. Wall Street Zen downgraded Innoviva from a “buy” rating to a “hold” rating in a research note on Sunday, May 17th. BTIG Research restated a “buy” rating and issued a $42.00 price target on shares of Innoviva in a research note on Tuesday, May 26th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Innoviva in a research note on Friday, March 27th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $36.20.

Innoviva Stock Performance

INVA opened at $21.51 on Tuesday. The business has a fifty day simple moving average of $22.89 and a 200 day simple moving average of $21.76. The company has a market capitalization of $1.59 billion, a PE ratio of 3.58 and a beta of 0.35. Innoviva has a 1 year low of $16.52 and a 1 year high of $25.15. The company has a debt-to-equity ratio of 0.19, a current ratio of 21.13 and a quick ratio of 20.07.

Innoviva (NASDAQ:INVA) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.01. The business had revenue of $97.99 million during the quarter, compared to the consensus estimate of $101.57 million. Innoviva had a return on equity of 33.33% and a net margin of 119.89%.

Institutional Trading of Innoviva

Institutional investors have recently modified their holdings of the stock. Parallel Advisors LLC lifted its position in shares of Innoviva by 82.8% during the 1st quarter. Parallel Advisors LLC now owns 1,179 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 534 shares during the period. EverSource Wealth Advisors LLC lifted its position in shares of Innoviva by 297.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,398 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 1,795 shares during the period. Danske Bank A S bought a new stake in shares of Innoviva during the 3rd quarter valued at $55,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Innoviva by 49.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,633 shares of the biotechnology company’s stock valued at $73,000 after acquiring an additional 1,197 shares during the period. Finally, Lazard Asset Management LLC bought a new stake in shares of Innoviva during the 2nd quarter valued at $92,000. 99.12% of the stock is currently owned by institutional investors.

Innoviva Company Profile

Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle.